Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H23NO3 |
Molecular Weight | 337.4122 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC\C=C1\C2=C(COC3=C1C=C(CC(O)=O)C=C3)C=CC=C2
InChI
InChIKey=JBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
Molecular Formula | C21H23NO3 |
Molecular Weight | 337.4122 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00768 | https://www.drugs.com/cdi/olopatadine-drops.html | http://reference.medscape.com/drug/patanase-olopatadine-intranasal-999491 | http://reference.medscape.com/drug/pataday-patanol-olopatadine-ophthalmic-343635 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021861s011lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00768 | https://www.drugs.com/cdi/olopatadine-drops.html | http://reference.medscape.com/drug/patanase-olopatadine-intranasal-999491 | http://reference.medscape.com/drug/pataday-patanol-olopatadine-ophthalmic-343635 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021861s011lbl.pdf
Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1350797 |
16.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PATANOL Approved UseINDICATIONS & USAGE SECTION PAZEO is indicated for the treatment of ocular itching associated with allergic conjunctivitis. PAZEO is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis. (1) Launch Date1996 |
|||
Primary | PATANASE Approved UseINDICATIONS AND USAGE. PATANASE Nasal Spray is an H1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. Launch Date2008 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.6 ng/mL |
1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered: |
OLOPATADINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.7 ng × h/mL |
1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered: |
OLOPATADINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.4 h |
1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered: |
OLOPATADINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Other AEs: Conjunctivitis viral, Hyperemia... Other AEs: Conjunctivitis viral (1.1%) Sources: Hyperemia (2.3%) Eyes tearing (1.1%) Eye discomfort (1.1%) Corneal staining (1.1%) |
1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Other AEs: Vision blurred, Dry eye... Other AEs: Vision blurred (4.8%) Sources: Dry eye (3.3%) Abnormal sensation in eye (2.1%) Corneal staining (2.4%) Conjunctival staining (1.8%) Eye pruritus (1.5%) Eye irritation (0.3%) Headache (1.5%) Dysgeusia (2.4%) Upper respiratory tract infection (1.8%) Nasopharyngitis (1.8%) Ligament sprain (0.3%) Cough (0.3%) |
1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
Other AEs: Eye discharge, Stinging... Other AEs: Eye discharge (4 patients) Sources: Stinging (4 patients) Blurred vision (4 patients) Dry nose (2 patients) Taste perversion (2 patients) |
1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Condition: ocular allergy | dry eye, mild-to-moderate Age Group: adult Sex: M+F Population Size: 25 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Conjunctivitis viral | 1.1% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Corneal staining | 1.1% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Eye discomfort | 1.1% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Eyes tearing | 1.1% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Hyperemia | 2.3% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 3-17 n = 88 Health Status: healthy Condition: asymptomatic eyes Age Group: 3-17 Sex: M+F Population Size: 88 Sources: |
Cough | 0.3% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Eye irritation | 0.3% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Ligament sprain | 0.3% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Eye pruritus | 1.5% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Headache | 1.5% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Conjunctival staining | 1.8% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Nasopharyngitis | 1.8% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Upper respiratory tract infection | 1.8% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Abnormal sensation in eye | 2.1% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Corneal staining | 2.4% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Dysgeusia | 2.4% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Dry eye | 3.3% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Vision blurred | 4.8% | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
healthy, 32.4 n = 330 Health Status: healthy Age Group: 32.4 Sex: M+F Population Size: 330 Sources: |
Dry nose | 2 patients | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
Taste perversion | 2 patients | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
Blurred vision | 4 patients | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
Eye discharge | 4 patients | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
Stinging | 4 patients | 1 drop 1 times / day multiple, ophthalmic Recommended Dose: 1 drop, 1 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 1 times / day Sources: |
unhealthy, 33 years (range: 4-77 years) n = 91 Health Status: unhealthy Condition: conjunctivitis, seasonal allergic Age Group: 33 years (range: 4-77 years) Sex: M+F Population Size: 91 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. | 2001 Jul |
|
Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. | 2002 Apr |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Histamine-induced vasodilation and vasoconstriction in the mesenteric resistance artery of the rat. | 2006 Jan 4 |
Patents
Sample Use Guides
0.1% solution (Patanol): 1 gtt BID in affected eye(s) at an interval of 6-8 hr
0.2% solution (Pataday): 1 gtt in affected eye(s) qDay
0.7% (Pazeo): 1 gtt in affected eye(s) qDay
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16864903
The migration of THP-1 monocytes was studied using a Chemotaxicell 24-well disposable chamber with 5 μm pores (Kurabo Industries Ltd, Osaka, Japan). Cultured cells were harvested and washed three times with Hank’s balanced salt solution and then resuspended in assay medium (RPMI 1640 with 0.5 vol% heat-inactivated FBS, 10 mmol/L N-(2-hydroxyethyl)piperazine-N’-(4-butanesulfonic acid), pH 7.4). Olopatadine and stimulant were premixed in the assay medium and incubated at 37◦C for 30min. Then 0.05mL of the mixture was placed into the lower chamber contained 0.45 mL/well of the assay medium. Then 0.2mL of cell suspension (6 x 10^5 cells) was added to the upper chamber and incubated for 3 h at 37◦C in 5% CO2. Cells passing through the membrane were collected from the lower well and counted with the EPICS XL/MCL flow cytometry system (Beckman Coulter, Fullerton, Calif, USA) followed by mixing of a predetermined number of flow-count fluorospheres (Beckman Coulter).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:50:39 GMT 2023
by
admin
on
Fri Dec 15 15:50:39 GMT 2023
|
Record UNII |
D27V6190PM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R01AC08
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
NDF-RT |
N0000175519
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
WHO-VATC |
QS01GX09
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
NDF-RT |
N0000000190
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
WHO-VATC |
QR01AC08
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
WHO-ATC |
S01GX09
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
||
|
NDF-RT |
N0000175628
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09431MIG
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
5281071
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
OLOPATADINE
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
m8204
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00768
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
7249
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
DTXSID3023390
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
D27V6190PM
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL1189432
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
Olopatadine
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
1986
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
7257
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
135391
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
113806-05-6
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
D27V6190PM
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
100000085473
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
C074921
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY | |||
|
C61866
Created by
admin on Fri Dec 15 15:50:39 GMT 2023 , Edited by admin on Fri Dec 15 15:50:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
primarily catalyzed by FMO1 and FMO3
MINOR
|
||
|
METABOLITE ACTIVE -> PARENT |
N-desmethyl olopatadine (Ml) formation was catalyzed mainly by CYP3A4
MAJOR
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||